Cognitive dysfunction and cancer: Which consequences in terms of disease management?

Psycho-Oncology

Volumn 20, Issue 12, 2011, Pages 1251-1258

  Joly, Florence ^a,b   Rigal, Olivier ^c   Noal, Sabine ^a   Giffard, Bénédicte ^d  

^a CENTRE FRANÇOIS BACLESSE   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c CENTRE HENRI BECQUEREL   (France)

^d UNIVERSITÉ DE CAEN   (France)

Author keywords

cancer; chemotherapy; cognition; neuropsychological tests; oncology

Indexed keywords

APOLIPOPROTEIN E4; CARBOPLATIN; CHOLINESTERASE INHIBITOR; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; FLUOROURACIL; GINKGO BILOBA EXTRACT; INTERLEUKIN 1; INTERLEUKIN 6; METHYLPHENIDATE; MODAFINIL; THIOTEPA; TUMOR NECROSIS FACTOR ALPHA;

AGE DISTRIBUTION; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SCREENING; CANCER SURVIVOR; CLINICAL PRACTICE; COGNITION; COGNITIVE DEFECT; CONCENTRATION LOSS; DATA BASE; DNA POLYMORPHISM; EDUCATIONAL STATUS; HEMATOLOGIC MALIGNANCY; HUMAN; INFORMATION PROCESSING; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MEDITATION; MEDLINE; MEMORY; NEOPLASM; NEUROPSYCHOLOGICAL TEST; PROSTATE CANCER; REVIEW; SOLID TUMOR; VELOCITY; VISUAL MEMORY; WORKING MEMORY;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; COGNITION DISORDERS; HUMANS; NEOPLASMS; SURVIVORS;

EID: 81755188352     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.1903     Document Type: Review

References (69)

1. Boykoff N, Moieni M, Subramanian SK,. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 2009; 3: 223-232.
2. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF,. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18: 2695-2701.
3. Ahles TA, Saykin A,. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 2001; 19: 812-820.
4. Bender CM, Sereika SM, Berga SL, et al., Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 2006; 15: 422-430.
5. Hurria A, Somlo G, Ahles T,. Renaming 'chemobrain'. Cancer Invest 2007; 25: 373-377.
6. Bial AK, Schilsky RL, Sachs GA,. Evaluation of cognition in cancer patients: special focus on the elderly. Crit Rev Oncol Hematol 2006; 60: 242-255.
7. Balducci L,. Management of cancer in the elderly. Oncology (Williston Park) 2006; 20: 135-143.
8. Vardy J, Rourke S, Tannock IF,. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007; 25: 2455-2463.
9. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB,. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008; 19: 623-629.
10. Nelson CJ, Nandy N, Roth AJ,. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care 2007; 5: 273-280.
11. Vardy J, Tannock I,. Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol 2007; 63: 183-202.
12. Chaturvedi SK, Venkateswaran C,. New research in psychooncology. Curr Opin Psychiatry 2008; 21: 206-210.
13. Mehlsen M, Pedersen AD, Jensen AB, Zachariae R,. No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psycho-Oncology 2009; 18: 248-257.
14. Brewin CR, Holmes EA,. Psychological theories of posttraumatic stress disorder. Clin Psychol Rev 2003; 23: 339-376.
15. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA,. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004; 100: 2292-2299.
16. Askins MA, Moore 3rd BD,. Preventing neurocognitive late effects in childhood cancer survivors. J Child Neurol 2008; 23: 1160-1171.
17. Butler RW, Sahler OJ, Askins MA, et al., Interventions to improve neuropsychological functioning in childhood cancer survivors. Dev Disabil Res Rev 2008; 14: 251-258.
18. Buizer AI, de Sonneville LM, Veerman AJ,. Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: a critical review of the literature. Pediatr Blood Cancer 2009; 52: 447-454.
19. Tannock IF, Ahles TA, Ganz PA, Van Dam FS,. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22: 2233-2239.
20. Taillibert S, Voillery D, Bernard-Marty C,. Chemobrain: is systemic chemotherapy neurotoxic? Curr Opin Oncol 2007; 19: 623-627.
21. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA,. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010; 116: 3348-3356.
22. Quesnel C, Savard J, Ivers H,. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 2009; 116: 113-123.
23. Ahles TA, Saykin AJ, McDonald BC, et al., Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010; 28: 4434-4440.
24. Winocur G, Vardy J, Binns MA, Kerr L, Tannock I,. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006; 85: 66-75.
25. Farlow MR,. Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? Alzheimers Res Ther 2010; 2: 15.
26. Ahles TA, Saykin AJ, Noll WW, et al., The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology 2003; 12: 612-619.
27. Ahles TA, Saykin AJ,. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007; 7: 192-201.
28. Chen D, Wu CF, Shi B, Xu YM,. Tamoxifen and toremifene impair retrieval, but not acquisition, of spatial information processing in mice. Pharmacol Biochem Behav 2002; 72: 417-421.
29. Wefel JS, Witgert ME, Meyers CA,. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 2008; 18: 121-131.
30. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S,. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psycho-Oncology 2009; 18: 811-821.
31. Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL,. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 2005; 96: 48-53.
32. Salminen EK, Portin RI, Koskinen AI, Helenius HYM, Nurmi MJ,. Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 2005; 103: 1381-1387.
33. Cherrier MM, Aubin S, Higano CS,. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psycho-Oncology 2009; 18: 237-247.
34. Joly F, Alibhai SM, Galica J, et al., Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 2006; 176: 2443-2447.
35. Nelson CJ, Lee JS, Gamboa MC, Roth AJ,. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008; 113: 1097-1106.
36. Mohile SG, Lacy M, Rodin M, et al., Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. J Geriatr Oncol 2010; 1: 13-19.
37. Patyna S, Laird AD, Mendel DB, et al., SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 2006; 5: 1774-1782.
38. Cumurciuc R, Martinez-Almoyna L, Henry C, Husson H, de Broucker T,. Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol (Paris) 2008; 164: 605-607.
39. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA,. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005; 59: 60-70.
40. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E,. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 2006; 20: 76-89.
41. Wieneke MH, Dienst ER,. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995; 4: 61-65.
42. Jenkins V, Shilling V, Deutsch G, et al., A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006; 94: 828-834.
43. van Dam FS, Schagen SB, Muller MJ, et al., Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210-218.
44. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF,. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85: 640-650.
45. Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C,. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology 2008; 17: 122-130.
46. Hurria A, Rosen C, Hudis C, et al., Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc 2006; 54: 925-931.
47. Whitney KA, Lysaker PH, Steiner AR, Hook JN, Estes DD, Hanna NH,. Is 'chemobrain' a transient state? A prospective pilot study among persons with non-small cell lung cancer. J Support Oncol 2008; 6: 313-321.
48. Minisini AM, De Faccio S, Ermacora P, et al., Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study. Crit Rev Oncol Hematol 2008; 67: 71-79.
49. Scherwath A, Mehnert A, Schleimer B, et al., Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 2006; 17: 415-423.
50. Ahles TA, Saykin AJ, Furstenberg CT, et al., Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20: 485-493.
51. Vezmar S, Becker A, Bode U, Jaehde U,. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003; 49: 92-104.
52. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S,. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psycho-Oncology 2009; 18: 134-143.
53. Fan HG, Houédé-Tchen N, Yi QL, et al., Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1-and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005; 23: 8025-8032.
54. Vardy J, Wong K, Yi QL, et al., Assessing cognitive function in cancer patients. Support Care Cancer 2006; 14: 1111-1118.
55. Folstein MF, Folstein SE, McHugh PR,. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
56. Mattis S., Mental Status Examination for organic mental syndrome in the elderly patient. In Geriatric Psychiatry: A Handbook for Psychiatrists and Primary Care Physicians, Bellak L, Karasu TB, (eds). Grune & Stratton: New York, 1976; 77-121.
57. Saykin AJ, Ahles TA, McDonald BC,. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 2003; 8: 201-216.
58. Silverman DH, Dy CJ, Castellon SA, et al., Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007; 103: 303-311.
59. O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al., Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005; 5: 439-446.
60. Fan HG, Park A, Xu W, et al., The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psycho-Oncology 2009; 18: 156-161.
61. Fenner MH, Ganser A,. Erythropoietin in cancer-related anemia. Curr Opin Oncol 2008; 20: 685-689.
62. Thompson SJ, Leigh L, Christensen R, et al., Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol 2001; 19: 1802-1808.
63. Lower E, Fleishman S, Cooper A, Zeldis J, Faleck H, Manning D,. A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and "chemobrain" in adult cancer patients. (ASCO meeting abstract). J Clin Oncol 2005; 23 (16 suppl): 8000.
64. Kohli S, Fisher SG, Tra Y, et al., The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009; 115: 2605-2616.
65. Lundorff LE, Jønsson BH, Sjøgren P,. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 2009; 23: 731-738.
66. Butler RW, Copeland DR, Fairclough DL, et al., A multicenter, randomized clinical trial of a cognitive remediation program for childhood survivors of a pediatric malignancy. J Consult Clin Psychol 2008; 76: 367-378.
67. Antoni MH, Lechner S, Diaz A, et al., Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer. Brain Behav Immun 2009; 23: 580-591.
68. Ferguson RJ, Ahles TA, Saykin AJ, et al., Cognitive-behavioral management of chemotherapy-related cognitive change. Psycho-Oncology 2007; 16: 772-777.
69. Biegler KA, Chaoul MA, Cohen L,. Cancer, cognitive impairment, and meditation. Acta Oncol 2009; 48: 18-26.